Advertisement
Document › Details
Atomwise, Inc.. (9/11/19). "Press Release: Atomwise Announces Largest China-US Collaboration for AI Drug Discovery". San Francisco, CA.
Atomwise could receive up to US$1.5 billion to develop first in-class and best in-class small molecules
Atomwise Inc. (“Atomwise”), the leader in artificial intelligence (AI) for drug discovery, today announced a collaboration with Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”), a leading biopharmaceutical company in China, to design and discover potential drug candidates for up to eleven undisclosed target proteins in multiple therapeutic areas.
“There is exciting science happening throughout Asia, and enormous potential for leadership in innovative drug discovery,” said Dr. Abraham Heifets, CEO of Atomwise. “I am delighted to announce that Hansoh Pharma is our first partner in Asia. Hansoh Pharma is committed to innovation and shares our mission for global impact on patient health,” he added.
Scientific teams from Atomwise and Hansoh Pharma will collaborate closely on the programs. The combination of Atomwise’s AI technology and medicinal chemistry and protein structure expertise, and Hansoh Pharma’s fully integrated research and development, manufacturing and commercial capabilities has the potential to dramatically increase success and compress timelines for drug discovery and clinical development.
Under the terms of the collaboration, Atomwise will receive undisclosed technology access fees, option exercise fees, royalties, and income based on sublicensing or sale of assets created under the collaboration. Based on historical average revenues for small molecule drugs, the total potential value of the deal to Atomwise with success in all projects could reach US$1.5 billion.
About Atomwise
Atomwise Inc. invented the first deep learning AI technology for structure-based small molecule drug discovery. Created in 2012, today Atomwise performs hundreds of projects per year in partnership with some of the world’s largest pharmaceutical and agrochemical companies, as well as over a hundred universities and hospitals in 19 countries. Atomwise has raised over $50 million from leading venture capital firms to support the development and application of its AI technology. Learn more at atomwise.com or follow @AtomwiseInc.
Media Contact
Sara Dunn
SDunn@jpa.com
Record changed: 2023-06-05 |
Advertisement
More documents for Atomwise Inc.
- [1] DeepCure, Inc.. (4/26/22). "Press Release: DeepCure Appoints Dr. Han Lim as Chief Business Officer". Boston, MA....
- [2] Celeris Therapeutics GmbH. (11/29/21). "Press Release: Celeris Therapeutics, Inc., Pioneering AI-driven Degrader Discovery, Appoints Nick DeHaan as VP, Head of Partnering". Menlo Park, CA....
- [3] Atomwise, Inc.. (12/21/20). "Press Release: Atomwise Announces Growing Portfolio of Joint Venture Companies". San Francisco, CA....
- [4] Atomwise, Inc.. (8/11/20). "Press Release: Atomwise Raises $123 Million in Series B Financing Co-Led by B Capital Group and Sanabil". San Francisco, CA....
- [5] Williams, Joe [Business Insider]. (7/17/20). "News: The Top 16 Companies Using Artificial Intelligence to Revolutionize Drug Discovery, According to Experts"....
- [6] Bayer AG. (1/7/20). "Press Release: Bayer Exercises Right to Enter into Follow-on Research and Collaboration Option Agreement with Atomwise. Companies to Continue Crop Protection Development Programs". Monheim & San Francisco, CA....
- [7] Atomwise, Inc.. (9/11/19). "Press Release: Atomwise and Atropos Launch Joint Venture to Discover Senescence Modulating Small Molecules for Cancer Patients". San Francisco, CA & Belmont, CA....
- [8] Atomwise, Inc.. (9/11/19). "Press Release: Hansoh Pharma and Atomwise Launch Strategic AI Drug Discovery Collaboration for Multiple Therapeutic Areas". Shanghai & San Francisco, CA....
- [9] Atomwise, Inc.. (9/10/19). "Press Release: Atomwise and OncoStatyx Announce Joint Venture to Develop Small Molecule Inhibitors of Oncology Target KDM5B". San Francisco, CA & Cleveland, OH....
- [10] Atomwise, Inc.. (9/10/19). "Press Release: SEngine Precision Medicine and Atomwise Announce Strategic Joint Venture to Accelerate Novel Drug Discovery". Seattle, WA & San Francisco, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top